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ORIGINAL RESEARCH ARTICLE
Diagnostic work-up in patients with possible asthma
referred to a university hospital
Vibeke Backer1*, Asger Sverrild1, Charlotte Suppli Ulrik2, Uffe Bødtger3,
Niels Seersholm4 and Celeste Porsbjerg1
1Respiratory Research Unit, Department of Respiratory Medicine, Bispebjerg University Hospital,
Copenhagen, Denmark; 2Department of Pulmonary Medicine, Hvidovre University Hospital, Copenhagen,
Denmark; 3Department of Respiratory Medicine, Næstved Hospital, Næstved, Denmark; 4Department of
Respiratory Medicine Y, Gentofte University Hospital, Copenhagen, Denmark
Objective: The best strategy for diagnosing asthma remains unclear. Accordingly, the aim of this study was to
evaluate diagnostic strategies in individuals with possible asthma referred to a respiratory outpatient clinic at
a university hospital.
Methods: All individuals with symptoms suggestive of asthma referred over 12 months underwent spirometry,
bronchodilator reversibility test, Peak expiratory flow rate (PEF) registration, and bronchial challenge test
with methacholine and mannitol on three separate days. The results of these tests were compared against an
asthma diagnosis based on symptoms, presence of atopy and baseline spirometry made by a panel of three
independent respiratory specialists.
Results: Of the 190 individuals examined, 63% (n122) were classified as having asthma. Reversibility to
b2-agonist had the lowest sensitivity of 13%, whereas airway hyperresponsiveness to methacholine had the
highest (69%). In contrast, specificity was the highest for reversibility testing (93%), whereas methacholine
had the lowest specificity (57%). The combination of reversibility, peak-flow variability, and methacholine
yielded a cumulative sensitivity of 78%, albeit a specificity of 41%. In comparison, a combination of
reversibility and mannitol resulted in a specificity of 82% and a sensitivity of 42%.
Conclusion: In this real-life population, different diagnostic test combinations were required to achieve a high
specificity for diagnosing asthma and a high sensitivity, respectively: Our findings suggest that the diagnostic
test approach should be based on whether the aim is to exclude asthma (high sensitivity required) or confirm
a diagnosis of asthma (high specificity required).
Keywords: Asthma management; diagnostic tools; airway hyperresponsiveness; spirometry; reversibility; sensitivity; specificity
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A
sthma is the most common chronic illness in
adolescents and young adults living in western
societies (1, 2). It is often under-diagnosed, which
may relate to variability of the disease over time and
between patients (3).
Asthma is characterized by respiratory symptoms
combined with variable and reversible airflow obstruction.
A diagnosis of asthma is objectively verified by the
demonstration of variable airflow obstruction, either by
reversibility to bronchodilators or steroids, spontaneous
variation assessed by peak expiratory flow rate monitor-
ing, or airway hyperresponsiveness (AHR) assessed by
airway challenge tests such as exercise, methacholine, or
mannitol (4). The diagnostic tools in asthma are numerous.
Although asthma can be diagnosed solely based on
relevant symptoms, in questionable cases, the diagnosis
should be confirmed by an objective measure.
Diagnostic tests are characterized by the sensitivity and
specificity. One test rarely performs well on both para-
meters but has either a high sensitivity (and the ability to
rule out disease in case of a negative test) or a high
specificity (and the ability to rule in disease in case of a
positive test) (5). An overlap between diagnostic tests for
asthma exists, but with a significant variation between
individuals, probably due to the heterogeneous nature of
what is currently identified or classified as ‘asthma’. It is
well known that reversibility to b2-agonists has a low
sensitivity due to many patients having a normal or near-
normal lung function (3, 6), and in these cases, bronchial
challenge testing is recommended to confirm the presence
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of the disease. Bronchial challenge tests have been designed
with a wide range of different stimuli, including exercise,
hyperventilation, hypertonic saline, mannitol, methacho-
line, and histamine, and all have different diagnostic
properties (5). However, the best combination of diagnos-
tic tests for asthma, including bronchial challenge tests, in
unselected asthma patients in a real-life situation, has yet
to be demonstrated. The aim of the present study was to
evaluate the different diagnostic tools and to determine the
best strategy for applying these tests in a real-life un-




This is a cross-sectional study of individuals with possible
asthma referred to the respiratory outpatient clinic at
Bispebjerg University hospital, Copenhagen, Denmark.
This group of patients is unselected and represent asthma
patient referred to a university hospital. The participants
were consecutively enrolled over 12 months (May 2012 to
April 2013) (Fig. 1). Exclusion criteria were respiratory
diseases other than asthma (e.g. sarcoidosis, chronic
obstructive pulmonary disease (COPD)), children younger
than 15 years, individuals older than 40 years with a
smoking history of more than 10 pack-years, pregnancy,
and recent respiratory infection (B6 weeks). All partici-
pants were assessed with a 3-day asthma evaluation
program (Table 1): (V1) interview and reversibility test;
(V2) methacholine provocation test, skin prick test, and
asthma control questionnaire (ACQ); (V3) fractional exhaled
nitric oxide (FeNO), mannitol provocation, and peak
expiratory flow (PEF) diary. A specialist panel evaluated
the diagnosis of asthma based on symptoms, family history
of atopy, and baseline lung function. The specialist diag-
nosis of asthma was used to evaluate the diagnostic
value of reversibility to b2-agonist (200 mL and 12%),
PEF variation (20%), and AHR to methacholine
(PD20B7.8 mmol) or AHR to mannitol (PD15B635 mg).
The study was approved by the local ethics committee
(H-3-2011-121).
Study population
A total of 256 patients with possible asthma (age 15 years
or more) were referred to the department during the
12-month study period from 1 May 2012 to 30 April 2013
(Fig. 1).
Evaluation algorithm
Height was measured in centimeters without shoes; weight
was measured in kilograms with the participant wearing
light clothing. BMI was calculated as weight in kg/height
in m2. Before all study visits, all participants were requested
to refrain from short- and long-acting b2-agonists for 12 h,
leukotriene antagonist for 24 h, and theophylline or
antihistamine for at least 24 h. Intensive exercise was not
allowed 6 h prior to mannitol testing, and furthermore
patients were asked to abstain from inhaled corticosteroid
(ICS) morning doses on the day of testing. In the case of an
FEV1B70%, challenges with mannitol and methacholine
were not performed.
MAPOUT II 2012 Flow Diagram
Assessed for eligibility (n=256)
Excluded: 21.5% (n=55)
Not meeting inclusion criteria: (n=17)
o Pregnant (n=5)
o Tobacco (n=11)
o Common cold (n=1)
Declined to participate: (n=32)
Other reasons: (n=6)
o Uncontrolled asthma (n=3)
o Language problems (n=3)
Completed (n=190; 74.2%)






Fig. 1. Flow-chart of the MapOut II study.
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Lung function was measured using maximum expiratory
flow volume according to the standards specified by the
ERS and ATS (7), using EasyOne (Spiropharma†).
Predicted normal values were calculated using NHANES
reference values (7), and percentages of predicted normal
values were then estimated. A reversibility test was
performed, using four puffs of terbutaline. A significant




Severity of asthma was classified according to the GINA
guidelines as well-controlled, partly controlled or uncon-
trolled (8, 9). Severity of symptoms was classified
according to the ACQ6 Juniper questionnaire (10), and
asthma quality of life was measured by a standard
questionnaire (miniAQLQ) (11). Tobacco consumption
was recorded; the average number of pack-years was
calculated for both smokers and ex-smokers [(average
number of cigarettes*years)/20].
Skin prick test
Skin prick test was performed according to European
standards with a panel of 10 standard allergen extracts
(12). A cutoff value of 3 mm defined atopy.
Methacholine bronchial provocation
The method of measuring airway responsiveness toward
inhaled methacholine has been described by Crapo et al. (13).
A Jaeger nebulizer generated the aerosols (Jaeger GmbH,
Germany) starting with a dose of isotonic saline followed
by increasing cumulated doses of methacholine, rang-
ing from 0.06 to 7.8 mol. Participants with an FEV1
reduction of 20% within a cumulative dose of methacho-
line of 57.8 mol have a positive test (PD20, i.e. AHR).
Visit V3
Mannitol bronchial provocation
The participants inhaled an empty capsule followed by
capsules with increasing doses of mannitol (from 5 to
635 mg) until maximum dose was reached or a 15%
reduction in FEV1 (PD15) was achieved (AHR, i.e.
a PD15, B635 mg) (14).
Flow variability (PEF)
All participants were instructed at Visit 1 (V1) to measure
PEF twice daily for 2 weeks and collection of the PEF
diary cards was done at Visit 3 (V3). A significant
variability was defined as a day-to-day variation of at
least 20% [(maximum  minimum)/maximum] (15).
Definition of asthma
The three independent specialists in respiratory medicine
(CSU, UB, and NS), employed at hospitals other than
Bispebjerg hospital, were e-mailed a file containing
information on respiratory symptoms, family history of
atopy and baseline spirometry (%pred), but not reversi-
bility testing. Based on these data, each specialist inde-
pendently decided whether each individual was ‘very likely
to have asthma’, ‘likely to have asthma’, ‘unlikely to
have asthma’, or ‘very unlikely to have asthma’. When
two out of three scored an individual as ‘very likely’ or
‘likely’ to have asthma, the individual was classified as
having asthma. In the event of two of the three specialists
scoring an individual as ‘unlikely’ or ‘very unlikely’ to have
asthma, the individual was classified as not having asthma.
Statistics
The data were analyzed with the statistical software
SPSS version 20.0 (Chicago, Illinois). Mean and standard
deviations (9SD) were calculated for the normally distri-
buted data. The chi-squared test was used when categorical
variables was used. For the continuous variables, data were
analyzed by ANOVA followed by the two-sample t-test to
compare the groups. Sensitivity, specificity, positive pre-
dictive values (PPV), and negative predictive values (NPV)
were calculated. Thereafter, the 95% confidence interval
(95% CI) was calculated for each value. The cumulated
sensitivity and specificity of the four different asthma tests
were measured. When describing the different strategies,
the selection of the test order was made from a clinician’s
point of view when selecting seven of the 16 possible
combinations. The test most often applied in the clinical
setting, the reversibility test, was selected as the first of the
many test strategies. Values of pB0.05 were considered
significant.
Results
Of the190 participants included, the specialist panel
classified 122 (64%) as having asthma. Of those referred,
150 had already been prescribed b2-agonist, of whom 45
Table 1. The distribution of tests performed on the three
separate visits within 23 weeks
Visit 1 (V1) Visit 2 (V2) Visit 3 (V3)
Informed consent Methacholine Collection of PEF cards




Tests included in the analysis of the diagnostic value of asthma
tests are written in italic.
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were later classified as non-asthmatic. All three specialists
suggested the same classification in 42% of the partici-
pants. Specialists S1 and S2 had a 65% [kappa coefficient
(k0.3)] overlap in their evaluations, and specialists S1
and S3 had a 64% (k0.2) overlap; specialists 2 and 3
had a 54% overlap (k0.1).
Those defined as having asthma were characterized by
more frequently being atopic, having not well-controlled
asthma, as assessed by ACQ (ACQ1.5: 48% vs. 18%,
pB0.001), and low quality of life score (miniAQLQ: 5.5
vs. 6.1, pB0.001, Table 2) compared with those without
asthma. On the other hand, no significant differences
were found between the two groups in baseline level of
lung function, reversibility to inhaled b2-agonist (12%) or
PEF day-to-day variation (20%) (Table 2). However,
those who were classified as having asthma more often
had AHR to both methacholine (69% vs. 47%, respec-
tively; pB0.01) and to mannitol (PD15 36% vs. 16%,
respectively; pB0.01) compared to those without asthma
(Table 2). Lastly, those classified as having asthma had
more often been prescribed anti-asthma therapy prior to
referral (Table 3).
As shown in Table 4, reversibility testing had the
lowest sensitivity for a diagnosis of asthma but the
highest specificity (11 and 95%, respectively), whereas
methacholine challenge had the highest sensitivity albeit
together with a low specificity (65 and 57%, respectively).
The outcome of the different combined test strat-
egies was analyzed, and the sensitivity and specificity
of seven test combinations are summarized in Table 5.
When applying all four tests, the cumulative sensitivity
reached 81%, albeit at the cost of a low specificity (41%).
When analyzing the combination with the highest speci-
ficity, reversibility testing and the mannitol test resulted in
a cumulative specificity of 75%, with a sensitivity of 42%.
Addition of peak-flow monitoring increased the sensitivity
to 54% but simultaneously decreased the specificity to 54%.
Lastly, in a real-life situation, patients referred under
the diagnosis possible asthma might be tested with
metacholine first, ‘‘to rule out’’ those without asthma.
A negative methacholine test was found in 50 (41%)
patients classified as likely to have asthma according to
the specialist panel, of whom 19 (17%) did not receive
treatment with ICS, and should, therefore, probably be
ruled out as having asthma. In comparison, of those
classified as ‘asthma unlikely’ by the specialist panel, 39
(62%) had a negative methacholine test, of whom 27
(45%) were not treated with ICS. Due to a negative
methacholine provocation, 46 (24%) patients were ruled
out as asthma patients. With this approach, 42% was
positive to methacholine only, further 20% were positive
to mannitol, 24% had day-to-day variation with PEF, and
13% showed bronchodilator reversibility.
In this group of patients with newly diagnosed asthma
having symptoms and a positive methacholine, the sensitivity
of reversibility testing, mannitol testing, and PEF varia-
tion was 13, 37, and 41%, respectively, with a specificity of
98, 91, and 64%, respectively.
Discussion
In this real-life asthma study examining unselected newly
referred patients with potential asthma using a selection
of asthma tests common in both asthma diagnosing and
management, we showed that no single test alone was the
Table 2. Baseline characteristics of the 190 patients with asthma-like symptoms enrolled in the present study
Non-specific respiratory
symptoms (n68) Asthma (n122) Total (n190) p
68 (36%) 122 (64%) 190 (100%)
% females 57 57 57 NS
% current hay fever 41 59 52 B0.05
Age [mean (SD)] 32.5 (13) 31.9 (13) 32.1 (13) NS
BMI 23.4 (3) 24.2 (5) 23.9 (4) NS
FEV1 L 3.8 (0.9) 3.7 (0.9) 3.8 (0.9) NS
FEV1 % predicted 97 (17) 95 (17) 95 (17) NS
% FEV1/FVC ratio 83 (9) 81 (10) 81 (10) NS
% with atopy 44 63 56 B0.01
% with AHR methacholine 47 65 62 B0.01
% with AHR mannitol 16 38 29 B0.01
% PEF cutoff20% 42 39 40 NS
% reversibility cutoff12% 8 13 11 NS
ACQ 0.9 (0.8) 1.6 (1.0) 1.3 (1.0) B0.001
% with ACQ1.5 18 48 37 B0.001
MiniAQLQ 6.1 (0.8) 5.5 (1.0) 5.7 (1.0) B0.001
Mean (SD) analyzed with t-test and percentage of column analyzed with X2-test.
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optimal test to use but that the diagnostic accuracy
increased with multiple testing. Overall, we showed that
with a combination of diagnostic tests, 81% of asthma
cases could be confirmed objectively in this population of
patients referred to a specialist asthma clinic.
The entire analysis of the diagnostic validity of the
different asthma tests has been both supported and
questioned in a recent review analyzing the similarities
and differences between BTS, NHBLI, and GINA guidelines
(16). Diagnostic tests for asthma have well-recognized
challenges, which include the practical feasibility of the
tests, the mismatch of sensitivity, and specificity of each
test, but also to the lack of a gold standard for the
diagnosis of asthma, which makes validation of diagnos-
tic tests difficult. The major drawback is the diversity of
the asthma phenotypes combined with the fact that many
patients with asthma symptoms also have other illnesses.
Asthma-like symptoms are frequently observed in other
non-asthmatic illnesses such as the early stages of COPD
(17), laryngeal obstruction (18, 19), gastroesophageal
reflux (19), poor physical fitness (20), sports-related
shortness of breath or cough (21), obese (22), and cardiac
diseases (23), and objective measurements are therefore
of significant importance and necessary to eliminate
misclassification.
The different asthma tests used in the present paper are
in accordance with the recommendations of the different
guidelines (10, 16), including the newly revised GINA
guidelines (24). We showed that these commonly used tests,
such as reversibility to b2-agonist and peak-flow day-to-
day variation, had limited usefulness in this tertiary setting
at a university hospital. The reversibility test had low
sensitivity, whereas the peak-flow variation showed a
better sensitivity but very low specificity for diagnosing
asthma (24). This was not substantially changed by
selecting those patients who had low lung function (13%
vs. 20%, data not shown); notably, it was not changed by
eliminating those treated with inhaled steroid at the time of
referral  in contrast, those patients had a higher response
than those who were untreated (17% vs. 8%, data not
shown). This suggests that patients who are prescribed ICS
by their GP are the ones who have more severe asthma, e.g.
a confounding effect, where those who have significant
AHR have more symptoms and hence are more likely to be
prescribed ICS.
The present survey does not support the recommenda-
tion of starting with reversibility testing before any
challenge testing, whereas the use of direct and indirect
challenge tests was found to have a better distribution
of sensitivity and specificity; methacholine had the
highest sensitivity for detection of asthma (Table 4), but
mannitol had the best association between sensitivity and
specificity (Table 4). These findings are somewhat differ-
ent from earlier findings in selected groups of asthma
patients (25) and random population studies (26, 27).
In an unselected group of young adults, the sensitivity of
methacholine and mannitol was found to be 80% for both
(27), which is substantially higher than in the present
study where the sensitivity to methacholine was 65% and
to mannitol 38%.
When applying all four diagnostic tests, we had a
success rate of 81% for detecting asthma. When starting
with a bronchial challenge test, the sensitivity increased
more rapidly than when using standard tests such as the
reversibility test and PEF variation (Table 5). A com-
bined sensitivity of 81% is relatively satisfactory in this
Table 3. Baseline anti-asthma treatment of the 190 patients with asthma-like symptoms enrolled in the present study
Non-specific respiratory symptoms Asthma Total p
68 (36%) 122 (64%) 190 (100%)
% ICS treateda 22 38 33 0.058
% ICS/LABA treateda 20 35 30 0.057
% b2 treatedb 66 86 79 0.01
aPatients with a history of inhaled steroid (ICS) with and without long-acting b2-agonist (LABA); bPatients with a history of bronchodilator
treatment.
Table 4. Sensitivity and specificity (including CI 95% in brackets), as well as positive predictive value of a positive test (PPV) and
a negative test (NPV) of selected variable of importance for the diagnosis of asthma
Sensitivity Specificity PPV NPV
b2 reversibility12% 13 (815) 93 (8597) 75 (5290) 36 (3338)
PEF variation20% 39 (3246) 58 (4869) 59 (4869) 39 (3146)
Mannitola 38 (3444) 82 (7189) 79 (6988) 42 (3746)
Methacholineb 65 (6475) 57 (4364) 74 (6880) 48 (3857)
ap0.015; bpB0.01.
Diagnostic work-up in asthma
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real-life asthma study performed in a hospital setting
where some patients had already been prescribed anti-
asthma therapy and others had not. When aiming for a
workable solution in the everyday clinical setting, this
study showed that such a solution should include either
mannitol or methacholine, depending on the clinical
setting. However, the specificity for mannitol was sub-
stantially higher than for testing with methacholine.
Although by their nature clinical guidelines are general
recommendations aimed toward implementation in the
clinical setting, they are generally based on the evidence
from studies of highly selected patient populations (24).
Accordingly, it is important that guideline recommendations
are also tested in real-life studies, such as the present
study and studies by others (28). When managing patients
with typical asthma-like symptoms, as in the GP setting,
guidelines might be focusing on symptoms, whereas those
in a hospital setting might be more diverse, and a symptoms-
based diagnosis is most likely inadequate (29). In a spe-
cialist setting, where the heterogeneity of asthma, with
co-morbidities and different asthma phenotypes, is more
the rule than the exception, these patients are more difficult to
diagnose, treat and monitor. The correct diagnosis of asthma
is paramount in achieving satisfactory asthma management
with treatment and to secure reduced levels of sickness,
unemployment, and early retirement (30, 31).
Table 5. Sensitivity and specificity of different combinations of diagnostic tests







Test Reversibility 12% 11 11 93
Strategy 1 AHR mannitol (PD15) 32 42 75
PEF variation 20% 12 54 54
AHR methacholine (PD20) 26 80 41
Negative results 20  
Test Reversibility12% 11 11 93
Strategy 2 PEF variation20% 21 32 63
AHR mannitol (PD15) 22 54 54
AHR methacholine (PD20) 26 80 41
Negative results 20  
Test Reversibility12% 11 11 93
Strategy 3 AHR methacholine (PD20) 46 57 54
PEF variation20% 21 78 41
AHR mannitol (PD15) 3 80 41
Negative results 20  
Test Reversibility 12% 11 11 93
Strategy 4 AHR mannitol (PD15) 32 42 75
PEF variation 20% 12 54 54
AHR methacholine (PD20) 26 80 41
Negative results 20  
Test AHR to methacholine (PD20) 65 65 57
Strategy 5 PEF variation20% 1 66 42
AHR to mannitol (PD15) 7 73 42
Reversibility12% 7 80 40
Negative results 20  
Test AHR to mannitol (PD15) 38 38 82
Strategy 6 AHR to methacholine (PD20) 35 73 56
PEF variation20% 7 79 43
Reversibility12% 1 80 41
Negative results 20  
Test AHR to methacholine (PD20) 65 65 57
Strategy 7 AHR to mannitol (PD15) 7 72 56
PEF variation20% 7 79 43
Reversibility12% 1 80 41
Negative results 20  
Vibeke Backer et al.
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With another approach, where all patients with asthma-
like symptoms and a negative provocation to methacholine
were ruled out as not having asthma, showed similar
findings toward testing with mannitol, PEF, and reversi-
bility testing, among those with certain asthma selected by
the specialist panel. High specificity was found with this
approach, even higher than found with the specialist
selection.
A potential limitation of the present study is the
diagnosis of asthma. We used a specialist panel to classify
the patients as having asthma or not having asthma.
Despite the members of the asthma panel all having
extensive clinical and scientific experience, the overlap
between their classifications was low, although the kappa
values were fair. However, under the given circumstances
with no gold standard, we believe this was the most
unbiased evaluation of disease taking the aim of evaluation
of diagnostics tests into account. Another limitation might
have been the wash-out period, which at least in patients
treated with ICS, might have been too short. On the other
hand, our results would be similar to findings among other
out-patients clinics. Lastly, although no cost analysis have
been performed, asthma testing is costly if all four
challenge tests are needed; on the other hand, asthma is
a chronic disease, and the diagnosis such be confirmed
objectively to avoid risk of overtreatment.
In conclusion, in this real-life population, different
diagnostic test combinations were required to achieve
a high specificity for diagnosing asthma, and a high
sensitivity, respectively. Our findings suggest that the
diagnostic test approach should be based on whether the
aim is to exclude asthma (high sensitivity required) or
confirm a diagnosis of asthma (high specificity required).
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